Science 37 Collaborates with AWS to Enable Faster, Patient-Friendly, Clinical Research
April 20 2023 - 7:59AM
Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research
industry-leading Metasite™, today announced a multi-year
relationship with Amazon Web Services (AWS) to scale and accelerate
adoption of the Science 37 Metasite, which provides clinical trial
sponsors the ability to securely engage with patients beyond
traditional clinical trial sites.
Science 37 will become a partner in the AWS Partner
Network (APN), which will help reach more customers and providers.
Science 37 will continue to leverage the security and reliability
of AWS, in addition to its analytics and machine learning (ML)
services to help improve decision-making, support patient safety,
and reduce the length of trial lifecycles.
“We are excited to join the AWS Partner Network
where we expect to leverage the global scale, expertise, and
security of AWS to reach more customers," said Michael Shipton,
Chief Commercial Officer at Science 37. “We also see an opportunity
to expand our network of partners to support patient recruitment
and methods of clinical conduct through these relationships, to
deliver faster, more inclusive, patient-friendly clinical
research.”
“AWS helps power the entire clinical development
process—from designing effective trials using analytics and ML
capabilities, to unlocking virtual trial capabilities, to
accelerating the regulatory submission process,” said Dan Sheeran,
General Manager, Healthcare and Life Sciences at Amazon Web
Services. “We look forward to working with Science 37 to extend the
capabilities and scale of the Metasite to help patients and
providers globally and enable their continued innovation. AWS will
continue to support Science 37 as they work to modernize clinical
research with faster trial enrollment, increased patient retention,
and more diverse patient populations.”
“This relationship supports the creation of an
environment that benefits clinical trial sponsors, patients, and
providers alike,” said Troy Bryenton, Chief Technology Officer,
Science 37. “AWS will help enable us to build scale, ensure safety
and security, build geo-specific datasets, and further our AL/ML
strategy while participating in the growing APN.”
About Science 37Science 37
Holdings, Inc.’s (Nasdaq: SNCE) mission is to accelerate clinical
research by enabling universal trial access for patients. Through
our Metasite™ we reach an expanded population beyond the
traditional site, delivering on our goal of clinical research that
works for everyone—with greater patient diversity. Patients gain
the flexibility to participate from the comfort of their own homes,
at their local community provider, or at a traditional site when
needed. Our Metasite is powered by a proprietary technology
platform with in-house medical and operational experts that drive
uniform study orchestration, enabling greater compliance and
high-quality data. To learn more, visit www.science37.com, or email
science37@science37.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains certain forward-looking
statements within the meaning of the federal securities laws,
including statements regarding the products offered by Science 37
and the markets in which it operates, and Science 37’s anticipated
growth and profitability. These forward-looking statements
generally are identified by the words “believe,” “can,” “could”,
“seek”, “project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “might”,
“should,” “will,” “would,” “will be,” “will continue,” “will likely
result” and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) the ability to maintain the listing of Science 37’s
securities on The Nasdaq Stock Market LLC, (ii) volatility in the
price of Science 37’s securities due to a variety of factors,
including changes in the competitive and highly regulated
industries in which Science 37 operates, variations in performance
across competitors, changes in laws and regulations affecting
Science 37’s business, changes in its capital structure, and
general economic and financial market conditions, including
fluctuations in currency exchange rates, economic instability, and
inflationary conditions (iii) the ability to implement business
plans, forecasts, and other expectations, and to identify and
realize additional opportunities, (iv) the risk that Science 37 may
never achieve or sustain profitability, (v) the risk that Science
37 will need to raise additional capital to execute its business
plan, which may not be available on acceptable terms or at all,
(vi) failure to realize anticipated cost savings, and (vii) risks
related to general economic and financial market conditions. The
foregoing list of factors is not exhaustive. You should carefully
consider the foregoing factors and the other risks and
uncertainties described in the “Risk Factors” section of Science
37’s Annual Report on Form 10-K for the fiscal year ended December
31, 2022 filed with the U.S. Securities and Exchange Commission
(the “SEC”) on March 6, 2023 and in the other documents filed by
Science 37 from time to time with the SEC. These filings identify
and address other important risks and uncertainties that could
cause actual events and results to differ materially from those
contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and Science 37 assumes no obligation and does not intend to update
or revise these forward-looking statements, whether as a result of
new information, future events, or otherwise, except as required by
law. Science 37 does not give any assurance that Science 37 will
achieve its expectations.
MEDIA INQUIRIES:Grazia
MohrenScience 37PR@science37.com
INVESTOR RELATIONS:Steve
HalperLifeSci AdvisorsInvestors@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jul 2023 to Jul 2024